


PRODUCT INFORMATION



Triazavirin

Item No. 36052

CAS Registry No.: 928659-17-0
Formal Name: 7-(methylthio)-3-nitro-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4(6H)-one, monosodium, dihydrate
Synonyms: Riamilovir, TZV
MF: $C_5H_3N_6O_3S \cdot Na [2H_2O]$
FW: 286.2
Purity: $\geq 95\%$
UV/Vis.: λ_{max} : 216, 254, 359 nm
Supplied as: A solid
Storage: $-20^\circ C$
Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Triazavirin is supplied as a solid. A stock solution may be made by dissolving the triazavirin in the solvent of choice, which should be purged with an inert gas. Triazavirin is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of triazavirin in these solvents is approximately 5 and 3 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of triazavirin can be prepared by directly dissolving the solid in aqueous buffers. The solubility of triazavirin in PBS (pH 7.2) is approximately 3 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Triazavirin is an antiviral agent.¹ *In vivo*, triazavirin (1 mg/kg) inhibits lung viral accumulation in a mouse model of H5N1 influenza A infection. Triazavirin (20 mg/kg) inhibits platelet aggregation in a rat model of LPS-induced hypercytokinemia.² Formulations containing triazavirin have been used in the treatment of influenza.

References

1. Loginova, S.I., Borisevich, S.V., Maksimov, V.A., *et al.* Therapeutic efficacy of Triazavirin, a novel Russian chemotherapeutic, against influenza virus A (H5N1). *Antibiot. Khimioter.* **56**(1-2), 10-12 (2011).
2. Spasov, A.A., Kucheryavenko, A.F., Sirotenko, V.S., *et al.* Antiplatelet activity of riamilovir under conditions of lipopolysaccharide intoxication. *Bull. Exp. Biol. Med.* **173**(1), 41-45 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM